We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

Exact Sciences’ Stool DNA Screening Technology Featured in Posters at Digestive Disease Week 2015

WASHINGTON— Exact Sciences Corp. (NASDAQ: EXAS) today announced that data supporting its stool DNA (sDNA) screening platform for colorectal cancer and other screening techniques for the detection of additional gastrointestinal cancers and diseases will be presented in five posters at Digestive Disease Week (DDW) 2015, taking place May 16-19 in Washington D.C. Recently approved by the U.S. Food and Drug Administration (FDA), Exact Sciences' noninvasive screening test Cologuard® uses sDNA technology to help detect the presence of colorectal cancer and precancer. Exact Sciences' technologies can be seen at the show at booth #1552.

"Building on the publication of strong clinical data supporting sDNA technology, followed by the FDA approval of Cologuard, we are pleased to see new clinical evidence backing this important screening option at this year's DDW conference," said Kevin Conroy, Chairman and CEO of Exact Sciences. "Studies like these will continue to drive awareness and adoption of Cologuard and provides Exact Sciences with the preliminary data needed to advance our product pipeline."

Poster Schedule:

Saturday, May 16 at 9:30 a.m., Hall C

  • Prevalence of DNA Biomarkers in Fecal Immunochemical Test Positive and Negative Colorectal Cancers
    Author available for Q&A: Barry M. Berger, Exact Sciences
  • Cost-effectiveness analysis of stool DNA or colonoscopy for colorectal neoplasia surveillance in patients with ulcerative colitis
    Author available for Q&A: David A. Ahlquist, M.D., Mayo Clinic
  • Molecular Detection of Colorectal Neoplasia: Do Markers that Target Acquired DNA Alterations in Sporadic Cases also Discriminate Lynch Syndrome Cases?
    Author available for Q&A: David A. Ahlquist, M.D., Mayo Clinic

Sunday, May 17 at 9:30 a.m., Hall C

  • Novel Epigenetic Markers for Detection of Esophageal Cancer: Selection By Whole Methylome Sequencing and Tissue Validation
    Author available for Q&A: David A. Ahlquist, M.D., Mayo Clinic
  • Test Performance Characteristics of Multi-Target Stool DNA Testing in African Americans and Caucasians
    Author available for Q&A: Barry M. Berger, Exact Sciences

Authors will be at their posters to answer questions from 12:00 p.m. to 2:00 p.m. on the day their posters are scheduled.

About Cologuard
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10, 000-patient pivotal trial were published in the New England Journal of Medicine in April 2014. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is listed in the screening guidelines of the U.S. Multi-Society Task Force on Colorectal Cancer.

Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.

About Exact Sciences Corp.
Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is included in the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, follow us on Twitter @ExactSciences or find us on Facebook.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, our ability to secure favorable reimbursement rates from Medicare and other third-party payors, timing of our launch of a commercial product, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

Exact Sciences
Cara Tucker
614-302-5622
ctucker@exactsciences.com
or
MSLGROUP
Jayme Maniatis and Rachel Gross
781-684-0770
exactsciences@mslgroup.com

 

Source: Exact Sciences Corp.

News Provided by Acquire Media

Topics: Exact Sciences News

Subscribe To The Blog